Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well niraparib and panitumumab work in
treating patients with colorectal cancer that has spread to other places in the body.
Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's
immune system attack the cancer and may interfere with the ability of tumor cells to grow and
spread. Giving niraparib and panitumumab may work better in treating patients with colorectal
cancer.